Biology of human cutaneous melanoma

Cancers

Volumn 2, Issue 1, 2010, Pages 165-189

  Elias, Elias G ^a   Hasskamp, Joanne H ^a   Sharma, Bhuvnesh K ^a  

^a Weinberg Cancer Institute   (United States)

Author keywords

Biology; Cutaneous; Melanoma; Therapeutic approaches

Indexed keywords

ALLOGENIC POLYVALENT SHED ANTIGEN VACCINE; ALPHA2B INTERFERON; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CURCUMIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; DNA VACCINE; GANGLIOSIDE GM2 VACCINE; GLYCOPROTEIN GP 100 PLUS MELAN A PLUS TYROSINASE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN VACCINE; IMATINIB; INTERFERON; INTERLEUKIN 2; MELACINE; MELAN A; MELANOMA VACCINE; OBLIMERSEN; PLACEBO; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA MELANOMA CELL LYSATE; VIRAL MELANOMA ONCOLYSATE; VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; CANCER SIZE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CELL HETEROGENEITY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG POTENTIATION; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INTESTINE CANCER; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; RADIOSURGERY; REVIEW; RNA INTERFERENCE; SENTINEL LYMPH NODE BIOPSY; SIGNAL TRANSDUCTION; SKIN SURGERY; SKIN ULCER; SOLID TUMOR; TUMOR IMMUNITY; WIDE EXCISION;

EID: 79952179431     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2010165     Document Type: Review

References (118)

1. Elias, E.G.; Didolkar, M.S.; Goel, I.P.; Formeister, J.F.; Valenzuela, L.A.; Pickren, J.L.; Moore, R.H. A clinicopathologic study of prognostic factors in cutaneous malignant melanoma. Surg. Gynecol. Obstet. 1977, 144, 327-334.
2. Wong, J.H.; Wanek, L.; Chang, L.J.; Goradia, T.; Morton, D.L. The importance of anatomic site in prognosis in patients with cutaneous melanoma. Arch. Surg. 1991, 126, 486-489.
3. Blois, M.S.; Sagebiel, R.W.; Abarbanel, R.M.; Caldwell, T.M.; Tuttle, M.S. Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival. Cancer 1983, 52, 1330-1341.
4. Weedon, D.; Strutton, G. Skin Pathology; Churchill Livingston: Edinburgh, London, UK, 1997; pp. 254-256.
5. Clark, W.H., Jr.; From, L.; Bernardino, E.A.; Mihm, M.C. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969, 29, 705-727.
6. Breslow, A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg. 1970, 172, 902-908.
7. Clark, W.H., Jr.; Elder, D.E.; Van Horn, M. The biologic forms of malignant melanoma. Hum. Pathol. 1986, 17, 443-450.
8. Balch, C.M.; Buzaid, A.C.; Soong, S.J.; Atkins, M.B.; Cascinelli, N.; Coit, D.G.; Fleming, I.D.; Gershenwald, J.E.; Houghton, A., Jr.; Kirkwood, J.M.; et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19, 3635-3648.
9. Balch, C.M.; Soong, S.J.; Gershenwald, J.E.; Thompson, J.F.; Reintgen, D.S.; Cascinelli, N.; Urist, M.; McMasters, K.M.; Ross, M.I.; Kirkwood, J.M.; et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, 19, 3622-3634.
10. Edge, S.B., Byrd, R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A., Eds. AJCC Cancer Staging Handbook, 7th ed.; Springer: New York, NY, USA, 2010; pp. 387-415.
11. Mascaro, J.M.; Castro, J.; Castel, T.; Lecha, M.; Gratacos, R.; Mascaro, J.M., Jr. Why do melanomas ulcerate? J. Cutan. Pathol. 1984, 11, 269-273.
12. Blessing, K.; McLaren, K.M. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992, 20, 315-322.
13. Ronan, S.G.; Eng, A.M.; Briele, H.A.; Shioura, N.N.; Das Gupta, T.K. Thin malignant melanomas with regression and metastases. Arch. Dermatol. 1987, 123, 1326-1330.
14. Slingluff, C.I., Jr.; Seigler, H.E. Thin malignant melanoma: risk factors and clinical management. Ann. Plast. Surg. 1992, 28, 89-94.
15. Kelly, J.W.; Sagebiel, R.W.; Blois, M.S. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer 1985, 56, 2287-2291.
16. Cooper, P.H.; Wanebo, H.J.; Hagar, R.W. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch. Dermatol. 1985, 121, 1127-1131.
17. Wanebo, H.J.; Cooper, P.H.; Hagar, R.W. Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann. Surg. 1985, 201, 499-504.
18. Clark, W.H., Jr.; Elder, D.E.; Guerry, D., 4th; Braitman, L.E.; Trock, B.J.; Schultz, D.; Synnestvedt, M.; Halpern, A.C. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 1989, 81, 1893-1904.
19. Sumner, W.C.; Foraker, A.G. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960, 13, 79-81.
20. Elias, E.G.; Didolkar, M.S.; Goel, I.P.; Formeister, J.F.; Valenzuela, L.Z.; Pickren, J.L.; Hebel, J.R. Deeply invasive cutaneous malignant melanoma. Surg. Gynecol. Obstet. 1981, 153, 67-70.
21. Bystryn, J.C.; Rigel, D.; Friedman, R.J.; Kopf, A. Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 1987, 123, 1053-1055.
22. Brocker, E.B.; Zwaldo, G.; Suter, L.; Brune, M.; Sorg, C. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol. Immunoth. 1987, 25, 81-86.
23. Torisu, H.; Ono, M.; Kiryu, H.; Furue, M.; Ohmoto, Y.; Nakayama, J.; Nishioka, Y.; Sone, S.; Kuwano, M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int. J. Cancer 2000, 85, 182-188.
24. Morton, D.L.; Essner, R.; Balch, C.M. Chapter 29. Surgical excision of distant metastases. In Cutaneous Melanoma, 4th ed.; Balch, C.M., Houghton, A.N., Sober, A.J., Soong, S.J., Eds.; Quality Medical Publishing Inc: St. Louis, MO, USA, 2003; pp. 547-572.
25. Lee, C.C.; Faries, M.B.; Wanek, L.A.; Morton, D.L. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J. Clin. Oncol. 2008, 26, 535-541.
26. Balch, C.M.; Soong, S.J.; Murad, T.M.; Smith, J.W.; Maddox, W.A.; Durant, J.R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1983, 1, 126-134.
27. Barth, A.; Wanek, L.A.; Morton, D.L. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg. 1995, 181, 193-201.
28. Fidler, I.J.; Gersten, D.M.; Hart, I.R. The biology of cancer invasion and metastasis. Adv. Cancer Res. 1978, 28, 149-250.
29. Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986, 46, 467-473.
30. Auerbach, W.; Auerbach, R. Angiogenesis inhibition: a review. Pharmacol. Ther. 1994, 63, 265-311.
31. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
32. Elias, E.G.; Hasskamp, J.H.; Mervin, B.J.; Growth factors and cytokines secreted by early passage human melanoma cell lines. 22nd Annual Scientific Meeting of the International Society for Biological Therapy of Cancer, Boston, MA, USA, November 2007; Abstract 45; J. Immunotherapy 2007, 30, 874.
33. Elias, E.G.; Hasskamp, J.H.; Sharma, B.K.; Beam, S.L.; McCarron, E.C.; Zapas, JL. Biological aspects of cutaneous melanoma with potential impact on target therapy. In Proceedings of the 99th American Association for Cancer Research Annual Meeting, San Diego, CA, USA, April 2008; Abstract 2151.
34. Rietschel, P.; Wolchok, J.D.; Krown, S.; Gerst, S.; Jungbluth, A.A.; Busam, K.; Smith, K.; Orlow, I.; Panageas, K.; Chapman, P.B. Phase II study of extended-dose temozolomide in patients with melanoma. J. Clin. Oncol. 2008, 26, 2299-2304.
35. Hill, G.J., II; Moss, S.E.; Golomb, F.M.; Grage, T.B.; Fletcher, W.S.; Minton, J.P.; Krementz, E.T. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG Protocol 7040. Cancer 1981, 47, 2556-2562.
36. Kirkwood, J.M.; Strawderman, M.H.; Ernstoff, M.S.; Smith, T.J.; Borden, E.C.; Blum, R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996, 14, 7-17.
37. McMasters, K.M.; Ross, M.I.; Reintgen, D.S.; Edwards, M.J.; Noyes, R.D.; Urist, M.; Sussman, J.; Goydos, J.; Beitsch, P.; Martin, R.C.; et al. Final results of the Sunbelt Melanoma Trial. In Proceedings of the 2008 American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, May 2008; Abstract 9003; J. Clin. Oncol. 2008, 26, 483S; 20 May 2008 supplement.
38. Rosenberg, S.A.; Yang, J.C.; Topalian, S.L.; Schwartzentruber, D.J.; Weber, J.S.; Parkinson, D.R.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994, 271, 907-913.
39. Atkins, M.B.; Kunkel, L.; Sznol, M.; Rosenberg, S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 2000, 6, S11-S14.
40. Rosenberg, S.A. Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J. Sci. Am. 1997, 3, S2-S6.
41. Rosenberg, S.A.; Yannelli, J.R.; Yang, J.C.; Topalian, S.L.; Schwartzentruber, D.J.; Weber, J.S.; Parkinson, D.R.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86, 1159-1166.
42. Kirkwood, J.M. Pharmacology of cancer biotherapeutics. In Cancer Principles and Practice of Oncology 2001, 6th ed.; Devita, V.Y., Hellman, S., Rosenberg, S.A., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA, USA, 2001; pp. 461-471.
43. Elias, E.G.; Zapas, J.L.; Beam, S.L.; Culpepper, W.J. Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up. Melanoma Res. 2007, 17, 310-315.
44. Spitler, L.E.; Grossbard, M.L.; Ernstoff, M.S.; Silver, G.; Jacobs, M.; Hayes, F.A.; Soong, S.J. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 2000, 18, 1614-1621.
45. Elias, E.G.; Zapas, J.L.; McCarron, E.C.; Beam, S.L.; Hasskamp, J.H.; Culpepper, W.J. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother. Radiopharm. 2008, 23, 285-291.
46. Hasskamp, J.H.; Elias, E.G.; Zapas, J.L. In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma. J. Clin. Immunol. 2006, 26, 331-338.
47. Daud, A.I.; Mirza, N.; Lenox, B.; Andrews, S.; Urbas, P.; Gao, G.X.; Lee, J.H.; Sondak, V.K.; Riker, A.I.; Deconti, R.C.; et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 2008, 26, 3235-3241.
48. Phan, G.Q.; Yang, J.C.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Restifo, N.P.; Haworth, L.R.; Seipp, C.A.; Freezer, L.J.; et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 2003, 100, 8372-8377.
49. Serafini, P.; Carbley, R.; Noonan, K.A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64, 6337-6343.
50. Filipazzi, P.; Valenti, R.; Huber, V.; Pilla, L.; Canese, P.; Iero, M.; Castelli, C.; Mariani, L.; Parmiani, G.; Rivoltini, L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25, 2546-2553.
51. Attia, P.; Phan, G.Q.; Maker, A.V.; Robinson, M.R.; Quezado, M.M.; Yang, J.C.; Sherry, R.M.; Topalian, S.L.; Kammula, U.S.; Royal, R.E.; et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23, 6043-6053.
52. Quezada, S.A.; Peggs, K.S.; Curran, M.A.; Allison, J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116, 1935-1945.
53. Wallack, M.K.; Sivanandham, M,; Balch, C.M.; Urist, M.M.; Bland, K.I.; Murray, D.; Robinson, W.A.; Flaherty, L.E.; Richards, J.M.; Bartolucci, A.A.; et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995, 75, 34-42.
54. Wallack, M.K.; Sivanandham, M.; Balch, C.M.; Urist, M.M.; Bland, K.I.; Murray, D.; Robinson, W.A.; Flaherty, L.; Richards, J.M.; Bartolucci, A.A.; et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 1998, 187, 69-77.
55. Hersey, P.; Edwards, A.; Coates, A.; Shaw, H.; McCarthy, W.; Milton, G. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol. Immunother. 1987, 25, 257-265.
56. Hersey, P.; Coates, A.S.; McCarthy, W.H.; Thompson, J.F.; Sillar, R.W.; McLeod, R.; Gill, P.G.; Coventry, B.J.; McMullen A, Dillon H; et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol. 2002, 20, 4181-4190.
57. Sosman, J.A.; Unger, J.M.; Liu, P.Y.; Flaherty, L.E.; Park, M.S.; Kempf, R.A.; Thompson, J.A.; Terasaki, P.I.; Sondak, V.K.; Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 2002, 20, 2067-2075.
58. Portoukalian, J.; Zwingelstein, G.; Doré, J.F. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur. J. Biochem. 1979, 94, 19-23.
59. Tsuchida, T.; Saxton, R.E.; Morton, D.L.; Irie, R.F. Gangliosides of human melanoma. J. Natl. Cancer Inst. 1987, 78, 45-54.
60. Livingston, P.O.; Wong, G.Y.; Adluri, S.; Tao, Y.; Padavan, M.; Parente, R.; Hanlon, C.; Calves, M.J.; Helling, F.; Ritter, G.; et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 1994, 12, 1036-1044.
61. Helling, F.; Zhang, S.; Shang, A.; Adluri, S.; Calves, M.; Koganty, R.; Longenecker, B.M.; Yao, T.J.; Oettgen, H.F.; Livingston, P.O. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995, 55, 2783-2788.
62. Ragupathi, G.; Livingston, P.O.; Hood, C.; Gathuru, J.; Krown, S.E.; Chapman, P.B.; Wolchok, J.D.; Williams, L.J.; Oldfield, R.C.; Hwu, W.J. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 2003, 9, 5214-5220.
63. Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 2001, 19, 2370-2380.
64. Eggermont, A.M.; Suciu, S.; Ruka, W.; Marsden, J.; Testori, A.; Corrie, P.; Aamdal, S.; Ascierto, P.A.; Patel, P.; Spatz, A.; EORTC Melanoma Group. EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. In Proceedings of the 2008 American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, May 2008; Abstract 9004; J. Clin. Oncol. 2008, 26, 484S; 20 May 2008 supplement.
65. Ribas, A.; Butterfield, L.H.; Glaspy, J.A.; Economou, J.S. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 2003, 21, 2415-2432.
66. Castelli, C.; Rivoltini, L.; Andreola, G.; Carrabba, M.; Renkvist, N.; Parmiani, G.J. T-cell recognition of melanoma-associated antigens. Cell Physiol. 2000, 182, 323-331.
67. Wang, F.; Bade, E.; Kuniyoshi, C.; Spears, L.; Jeffery, G.; Marty, V.; Groshen, S.; Weber, J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 1999, 5, 2756-2765.
68. Smith, J.W., II; Walker, E.B.; Fox, B.A.; Haley, D.; Wisner, K.P.; Doran, T.; Fisher, B.; Justice, L.; Wood, W.; Vetto, J.; et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. 2003, 21, 1562-1573.
69. Rosenberg, S.A.; Sherry, R.M.; Morton, K.E.; Scharfman, W.J.; Yang, J.C.; Topalian, S.L.; Royal, R.E.; Kammula, U.; Restifo, N.P.; Hughes, M.S.; et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 2005, 175, 6169-6176.
70. Hu, X.; Chakraborty, N.G.; Sporn, J.R.; Kurtzman, S.H.; Ergin, M.T.; Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996, 56, 2479-2483.
71. Kruit, W.H.J.; van Ojik, H.H.; Brichard, V.G.; Escudier, B.; Dorval, T.; Dréno, B.; Patel, P.; van Baren, N.; Avril, M.; Piperno, S.; et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Inter. J. Cancer 2005, 117, 596-604.
72. Pullarkat, V.; Lee, P.P.; Scotland, R.; Rubio, V.; Groshen, S.; Gee, C.; Lau, R.; Snively, J.; Sian, S.; Woulfe, S.L.; et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin. Cancer Res. 2003, 9, 1301-1312.
73. Belli, F.; Testori, A.; Rivoltini, L.; Maio, M.; Andreola, G.; Sertoli, M.R.; Gallino, G.; Piris, A.; Cattelan, A.; Lazzari, I.; et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 2002, 20, 4169-4180.
74. Testori, A.; Richards, J.; Whitman, E.; Mann, G.B.; Lutzky, J.; Camacho, L.; Parmiani, G.; Tosti, G.; Kirkwood, J.M.; Hoos, A.; et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 2008, 26, 955-962.
75. de Vries. I.J.; Bernsen, M.R.; Lesterhuis, W.J.; Scharenborg, N.M.; Strijk, S.P.; Gerritsen, M.J.; Ruiter, D.J.; Figdor, C.G.; Punt, C.J.; Adema, G.J. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 2005, 23, 5779-5787.
76. Bedrosian, I.; Mick, R.; Xu, S.; Nisenbaum, H.; Faries, M.; Zhang, P.; Cohen, P.A.; Koski, G.; Czerniecki, B.J. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J. Clin. Oncol. 2003, 21, 3826-3835.
77. Smith, S.G.; Patel, P.M.; Porte, J.; Selby, P.J.; Jackson, A.M. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin. Cancer Res. 2001, 7, 4253-4261.
78. Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M.; Topalian, S.L.; Restifo, N.P.; Dudley, M.E.; Schwarz, S.L.; Spiess PJ.; et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4, 321-327.
79. Rosenberg, S.A.; Zhai, Y.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M.; Topalian, S.L.; Restifo, N.P.; Seipp, C.A.; Einhorn, J.H.; et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 1998, 90, 1894-1900.
80. Toda, M.; Martuza, R.L.; Kojima, H.; Rabkin, S.D. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 1998, 160, 4457-4464.
81. Bystryn, J.C.; Henn, M.; Li, J.; Shroba, S. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res. 1992, 52, 5948-5953.
82. Bystryn, J.C.; Zeleniuch-Jacquotte, A.; Oratz, R.; Shapiro, R.L.; Harris, M.N.; Roses, D.F. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. 2001, 7, 1882-1887.
83. Reynolds, S.R.; Zeleniuch-Jacquotte, A.; Shapiro, R.L.; Roses, D.F.; Harris, M.N.; Johnston, D.; Bystryn, J.C. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 2003, 9, 657-662.
84. Elias, E.G.; Tomazic, V.J.; Buda, B.S. Adjuvant immunotherapy in melanoma: a new approach. J. Surg. Oncol. 1992, 50, 144-148.
85. Barth, A.; Hoon, D.S.; Foshag, L.J.; Nizze, J.A.; Famatiga, E.; Okun, E.; Morton, D.L. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 1994, 54, 3342-3345.
86. Morton, D.L.; Foshag, L.J.; Hoon, D.S; Nizze, J.A; Famatiga, E; Wanek, L.A.; Chang, C.; Davtyan, D.G.; Gupta, R.K.; Elashoff, R.; et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 1992, 216, 463-482.
87. Morton, D.L.; Barth, A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin. 1996, 46, 225-244.
88. Morton, D.L.; Hsueh, E.C.; Essner, R.; Foshag, L.J.; O'Day, S.J.; Bilchik, A.; Gupta, R.K.; Hoon, D.S.; Ravindranath, M.; Nizze, J.A.; et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg. 2002, 236, 438-448.
89. Elias, E.G. Melanoma vaccines. A review. G. Ital. Dermatol. Venereol 2006, 141, 33-43.
90. Elias, E.G.; Suter, C.M.; Fabian, D.S. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J. Surg. Oncol. 1997, 64, 17-22.
91. Berd, D.; Maguire, H.C., Jr.; Schuchter, L.M.; Hamilton, R.; Hauck, W.W.; Sato, T.; Mastrangelo, M.J. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 1997, 15, 2359-2370.
92. Berd, D.; Sato, T.; Maguire, H.C., Jr.; Kairys, J.; Mastrangelo, M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 2004, 22, 403-415.
93. Chin, L.; Garraway, L.A.; and Fisher, D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20, 2149-2182.
94. Lobbezoo, M.W.; Giaccone, G.; Van Kalken, C. Signal transduction modulators for cancer therapy: from promise to practice? Oncologist 2003, 8, 210-213.
95. Collins, I.; Workman, P. Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets. Curr. Signal Transduct. Ther. 2006, 1, 13-23.
96. Lázár-Molnár, E.; Hegyesi, H.; Tóth, S.; Falus, A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12, 547-554.
97. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445, 851-857.
98. Meier, F.; Busch, S.; Lasithiotakis, K.; Kulms, D.; Garbe, C.; Maczey, E.; Herlyn, M.; Schittek, B. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 2007, 156, 1204-1213.
99. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4-25.
100. Waksal, H.W. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 1999, 18, 427-436.
101. Selzer, E.; Schlagbauer-Wadl, H.; Okamoto, I.; Pehamberger, H.; Pötter, R.; Jansen, B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res. 1998, 8, 197-203.
102. Sarbassov, D.D.; Ali, S.M.; Sabatini, D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17, 596-603.
103. Thompson, C.B.; Allison, J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997, 7, 445-450.
104. Lux, M.L.; Rubin, B.P.; Biase, T.L.; Chen, C.J.; Maclure, T.; Demetri, G.; Xiao, S.; Singer, S.; Fletcher, C.D.; Fletcher, J.A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000, 156, 791-795.
105. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
106. McDermott, D.F.; Sosman, J.A.; Gonzalez, R.; Hodi, F.S.; Linette, G.P.; Richards, J.; Jakub, J.W.; Beeram, M.; Tarantolo, S.; Agarwala, S.; et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 2008, 26, 2178-2185.
107. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae P, Mietlowski W.; et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354, 2542-2551.
108. Talpaz, M.; Shah, N.P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354, 2531-2541.
109. Juarez, J.C.; Betancourt, O., Jr.; Pirie-Shepherd, S.R.; Guan, X.; Price, M.L.; Shaw, D.E.; Mazar, A.P.; Doñate, F. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin. Cancer Res. 2006, 12, 4974-4982.
110. Hinrichs, C.S.; Borman, Z.A.; Cassard, L.; Gattinoni, L.; Spolski, R.; Yu, Z.; Sanchez-Perez, L.; Muranski, P.; Kern, S.J.; Logun, C.; et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 2009, 106, 17469-17474.
111. Johnson, L.A.; Morgan, R.A.; Dudley, M.E.; Cassard, L.; Yang, J.C.; Hughes, M.S.; Kammula, U.S.; Royal, R.E.; Sherry, R.M.; Wunderlich, J.R.; et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114, 535-546.
112. Tao, J.; Tu, Y.T.; Huang, C.Z.; Feng, A.P.; Wu, Q.; Lian, Y.J.; Zhang, L.X.; Zhang, X.P.; Shen, G.X. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br. J. Dermatol. 2005, 153, 715-724.
113. Elbashir, S.M.; Lendeckel, W.; Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15, 188-200.
114. Akhtar, S.; Benter, I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 2007, 59, 164-182.
115. Zabierowski, S.E.; Herlyn, M. Melanoma stem cells: the dark seed of melanoma. J. Clin. Oncol. 2008, 26, 2890-2894.
116. Klein, W.M.; Wu, B.P.; Zhao, S.; Wu, H.; Klein-Szanto, A.J.; Tahan, S.R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20, 102-107.
117. Sharma, B.K.; Manglik, V.; Elias, E.G. Identification of melanoma stem cell markers in human cutaneous melanoma. J. Surg. Res. 2010, 158, 400.
118. Hasskamp, J.H.; Elias, E.G.; Avergas, A.; Sharma, B.K.; Zapas, JL. Inhibition of proliferation of early passage human melanoma cell lines by curcumin. Proceedings of the 99th American Association for Cancer Research Annual Meeting, San Diego, CA, USA, April 2008; Abstract 617.